CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 71 enrolled
Drug / intervention
INS018_055 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05938920
NCT05938920Phase 2Completed
CompareCT.gov

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

InSilico Medicine Hong Kong Limited·interventional·Posted Jul 11, 2023·Updated Dec 11, 2025

In Brief

A Phase 2 clinical trial evaluating INS018_055 and Placebo for Idiopathic Pulmonary Fibrosis (IPF). Completed, enrolled 71 participants across 22 sites.

Detailed Summary

The goal of this clinical trial is to learn about INS018\_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018\_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis (IPF)
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedJul 11, 2023
Enrollment StartJun 19, 2023
Primary CompletionAug 8, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 3.0 years ago

Interventions

INS018_055drug

Pharmaceutical formulation: Capsules Mode of Administration: Oral

Placebodrug

Pharmaceutical formulation: Capsules Mode of Administration: Oral